Juhe Bio

Juhe Bio (Beijing Origin Juhe Biotechnology) is a leading Chinese biotechnology company specializing in the early detection and non-invasive screening of gynecological malignancies. Leveraging a proprietary DNA methylation detection platform, the company develops high-sensitivity molecular diagnostic kits for cervical, endometrial, and ovarian cancers. Its flagship product, Ciscer®, is a pioneering NMPA-approved methylation screening test for cervical cancer, while Cisendo® provides a breakthrough non-invasive diagnostic for endometrial cancer. Backed by top-tier investors such as Prosperity7 Ventures (Aramco) and ZhenFund, Juhe Bio aims to transform women’s oncology care by replacing invasive procedures with accurate, cost-effective epigenetic molecular diagnostics. The company maintains GMP-certified manufacturing facilities in Beijing and is expanding its reach into global markets.